H.C. Wainwright lowered the firm’s price target on Zentalis to $46 from $55 and keeps a Buy rating on the shares post the Q3 report. The analyst views the share weakness as unwarranted, saying azenosertib is approvable and competitive against ADCs. The firm believes azenosertib “continues to garner an impressive profile.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZNTL:
- Zentalis price target lowered to $29 from $50 at Wells Fargo
- Zentalis selloff ‘misses the bigger picture,’ says Oppenheimer
- Zentalis CSO Kevin Bunker to step down, Mark Lackner to succeed
- Zentalis announces updated data from Phase 1 trial of azenosertib
- Zentalis expects cash to fund operations into 2026
